Search Medical Condition
Please enter condition
Please choose location from dropdown
Clear Trial Filters
 

Familial Hypercholesterolemia Clinical Trials

A listing of Familial Hypercholesterolemia medical research trials actively recruiting patient volunteers. Search for closest city to find more detailed information on a research study in your area.

RESULTS

Found (15) clinical trials

Study of AKCEA-ANGPTL3-LRX (ISIS 703802) in Patients With Homozygous Familial Hypercholesterolemia (HoFH)

This is a single center, open-label study to evaluate the efficacy of AKCEA-ANGPTL3- LRX for reduction of low density lipoprotein cholesterol (LDL-C) levels in patients with Homozygous Familial Hypercholesterolemia (HoFH).

Phase

A Gene Therapy Study for Homozygous Familial Hypercholesterolemia (HoFH)

Subjects will be asked to participate in an optional kinetics study. Subjects who agree will be admitted to the research inpatient unit at University of Pennsylvania or selected sites for the LDL kinetics study prior to vector administration. The LDL kinetic assessment will be performed using a primed constant infusion ...

Phase

HDL Acute Lipid Optimization in Homozygous Familial Hypercholesterolemia

The PDS-2 System is intended to reduce coronary atheroma in patients with Homozygous Familial Hypercholesterolemia (HoFH). Subjects will receive serial infusions of autologous selectively delipidated HDL/pre enriched plasma following use of HDL Therapeutics' PDS-2 System.

Phase N/A

Safety Tolerability Pharmacokinetics and Pharmacodynamics of IONIS ANGPTL3-LRx in Healthy Volunteers With Elevated Triglycerides and Subjects With Familial Hypercholesterolemia

The purpose is to assess the safety, tolerability, pharmacokinetics, and pharmacodynamics of IONIS ANGPTL3-LRx (ISIS 703802) given to healthy volunteer subjects with elevated triglycerides and subjects with familial hypercholesterolemia.

Phase

An Extension Trial of Inclisiran Compared to Evolocumab in Participants With Cardiovascular Disease and High Cholesterol

ORION-3, an extension of study MDCO-PCS-15-01 (ORION-1) [NCT02597127], is a Phase II, placebo-controlled, double-blind, randomized trial to evaluate the efficacy, safety, and tolerability of inclisiran (ALN-PCSSC) injection(s). All participants who completed ORION-1 (at least up to and including Day 210) and meet the study criteria will be enrolled into this ...

Phase

Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable Lipid-Lowering Therapy (COBALT-1)

The purpose of this study is to assess the efficacy, safety, and tolerability of multiple doses of Gemcabene in patients with HoFH on stable, lipid-lowering therapy.

Phase

Efficacy and Safety of Fenofibrate Added on to Atorvastatin Compared With Atorvastatin

Multi center, randomized, double-blind, parallel-group, therapeutic confirmatory study Primary Outcome Measure: The mean percent change of Non-HDL Cholesterol [Time Frame: from baseline at week 8] Secondary Outcome Measures: The achievement rate of LDL-C<100mg/dl, Non-HDL-C<130mg/dl [Time Frame: from baseline at week 8] The mean percent change of LDL-C, HDL-C, TG, TC, ...

Phase

Effect of Rapeseed Oil and Sunflower Oil

Familial hypercholesterolemia (FH), an inherited disorder of lipoprotein metabolism, is a risk for early cardiovascular disease (CVD). This autosomal dominant disease is characterized by markedly elevated plasma concentrations of low density lipoprotein (LDL) and total cholesterol (TC). The purpose of this study is to compare the effect of a diet ...

Phase N/A

Evaluation of Chylomicrons Metabolism in Sub-Clinical Atherosclerosis in Patients Whit Heterozigous Familial Hypercholesterolemia (FH) Treated With Statin Plus Ezetimibe

Study Title: Evaluation of chylomicrons metabolism in sub-clinical atherosclerosis in patients whit Heterozigous Familial Hypercholesterolemia (FH) treated with statin plus ezetimibe. Background: Coronary artery calcification (CAC) is a marker of sub-clinical coronary atherosclerosis which correlates with higher risk of clinical events. It was already demonstrated that CAC is more prevalent ...

Phase N/A

Trial Assessing Efficacy Safety and Tolerability of PCSK9 Inhibition in Paediatric Subjects With Genetic LDL Disorders

A study to evaluate the effect of 24 weeks of subcutaneous (SC) evolocumab compared with placebo,when added to standard of care, on percent change from baseline in lowdensity lipoprotein cholesterol (LDL-C) in pediatric subjects 10 to 17 years of age with HeFH

Phase